# A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

> **NCT02446418** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 423 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Furoate
- **DRUG:** Vilanterol
- **DRUG:** Fluticasone propionate
- **DRUG:** Salmeterol
- **DRUG:** Budesonide
- **DRUG:** Formoterol Fumarate

## Key facts

- **NCT ID:** NCT02446418
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-09
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02446418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02446418, "A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02446418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*